Subscribe to RSS
DOI: 10.1055/s-0039-1697645
Auditory and Vestibular Side Effects of FDA-Approved Drugs for Diabetes
Publication History
Publication Date:
09 October 2019 (online)
![](https://www.thieme-connect.de/media/sih/201904/lookinside/thumbnails/10-1055-s-0039-1697645_00815-1.jpg)
Abstract
As of September 10, 2019, there were 75 medications (oral/injectable/inhalants) approved by the U.S. Food and Drug Administration for diabetes management: 1 inhalant, 21 oral combinations, 22 injectable, and 31 oral medications (not in combination with any other diabetes drug). This article isolates the auditory and vestibular side effects of those drugs as reported by the drug's manufacturer as well as those side effects that could interfere with a balance assessment. Twenty of the 75 approved medications (26%) could have an auditory-related side effect. Hearing loss and tinnitus are not on the list. Only two, or just 3%, have vertigo and spinning as reported side effects (one each). More than 50% of the drugs will have some effect on a balance assessment. Audiologists who evaluate a patient with diabetes (PWD) are presented with symptoms that could be related to their diabetes medication. Although the manufacturer might report a side effect as rare or as a percentage from their clinical trials subjects, not all PWD will experience these adverse events. Auditory and vestibular side effects do not dominate the diabetes drug side effect list, but, rather, the most reported side effects could impact a balance assessment. The lists that appear in [Appendices A] and [B] should serve as a guide for all professionals involved in managing the PWD (i.e., audiologists, otolaryngologists, diabetes educators, pharmacists, optometrists, dentists, etc.). The list also serves as a counseling tool if a communication problem emerges during the progression of the diabetes.
-
References
- 1 White Jr JR. A brief history of the development of diabetes medications. Diabetes Spectr 2014; 27 (02) 82-86
- 2 DiSogra RM. Diabetes medication side effects on hearing, balance and cognition. Audiol Project 2018. Available at: www.theaudiologyproject.com . Accessed December 21, 2018
- 3 MedLine Plus. Available at: https://medlineplus.gov/ [Search DIABETES]. Accessed December 10, 2018
- 4 ClinicalTrials.gov. Available at: www.clinicaltrials.gov . Accessed May 6, 2019
- 5 DiSogra RM. Communication strategies. Available at: https://drbobdisogra.com/communication-strategies . Accessed December 19, 2018
- 6 Botelho CT, Carvalho SA, Silva IN. Increased prevalence of early cochlear damage in young patients with type 1 diabetes detected by distortion product otoacoustic emissions. Int J Audiol 2014; 53 (06) 402-408
- 7 Elamin A, Fadlallah M, Tuevmo T. Hearing loss in children with type 1 diabetes. Indian Pediatr 2005; 42 (01) 15-21
- 8 Maia CA, Campos CA. Diabetes mellitus as etiological factor of hearing loss. Rev Bras Otorrinolaringol (Engl Ed) 2005; 71 (02) 208-214
- 9 Hlayisi VG. , et al. High prevalence of disabling hearing loss in young to middle – aged adults with diabetes. Int J Diabetes Devel Count 2019; 39 (01) 148-153
- 10 Noreña AJ. Revisiting the cochlear and central mechanisms of tinnitus and therapeutic approaches. Audiol Neurotol 2015; 20 (Suppl. 01) 53-59
- 11 Kircher ML, Standring RT, Leonetti JP. Neuroradiologic assessment of pulsatile tinnitus. Otolaryngol Head Neck Surg 2008; 139 (Suppl): 1-17 , 144
- 12 Gans RE. Dizziness, vertigo and falls in persons with diabetes. Audiol Proj 2018. Available at: www.audiologist.org/item/dizziness-vertigo-and-falls-in-persons-with-diabetes . Accessed August 29, 2019